IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 426, 469 & 493**

ORDER AUTHORIZING THE ASSUMPTION AND ASSIGNMENT OF CERTAIN DESIGNATED ASSIGNED CONTRACTS TO PTC THERAPEUTICS, INC.

Pursuant to the *Order (A) Authorizing the Sale of the Debtor's Assets Free and Clear of All Liens, Claims, Interests, and Encumbrances; (B) Approving Assumption and Assignment of the Assigned Contracts; and (C) Granting Related Relief* [Docket No. 426] (the "**PTC Sale Order**")[2] and the Purchase Agreement, and this Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157 and 1334 and the *Amended Standing Order of Reference* of the United States District Court for the District of Delaware, dated February 29, 2012; and this Court having previously entered the PTC Sale Order; and the Debtor having filed the *First Notice of Previously Omitted Contracts Designated as Assigned Contract in Connection with Fabry Sale Transaction* [Docket No. 469] (the "**Designation Notice**") concerning those certain Previously Omitted Contracts designated as Assigned Contracts (the "**Designated Assigned Contracts**") in connection with the Sale; and as evidenced by the *Certificate of Service* [Docket No. 480] filed with the Court regarding the Designation Notice, proper, timely, adequate, and sufficient notice of the

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 7000 Marina Blvd., Brisbane, CA 94005.

[2] Capitalized terms used but not defined herein have the meanings given to them in the PTC Sale Order or the Purchase Agreement, as applicable.

2610989261002000000000001

Designation Notice has been provided; and each applicable counterparty to each Designated Assigned Contract having had an adequate opportunity to object to the Cure Costs and to the assumption and assignment to PTC of the applicable Designated Assigned Contract, including objections related to the provision of adequate assurance of future performance by PTC; and in connection with the *Certification of Counsel Regarding Order Authorizing the Assumption and Assignment of the Designated Assigned Contracts* brought before this Court; and after due deliberation and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT

1. In accordance with the terms of the PTC Sale Order and the Purchase Agreement, the assumption and assignment of the Designated Assigned Contracts identified on **Exhibit 1** hereto to PTC is hereby approved as set forth herein and in the PTC Sale Order, and the Debtor is authorized to assume and assign the Designated Assigned Contracts to PTC pursuant to sections 105(a), 363, and 365 of the Bankruptcy Code. The Designated Assigned Contracts are hereby Assigned Contracts for all purposes under the PTC Sale Order and the Purchase Agreement, and all provisions thereof (including, without limitation, all findings of fact contained in the PTC Sale Order) relating to Assigned Contracts shall be applicable to the Designated Assigned Contracts. The assumption and assignment of the Designated Assigned Contracts shall be effective as of the Closing Date.

2. Nothing in this Order is intended to amend, supersede, or modify the PTC Sale Order or the Purchase Agreement.

3. The Debtor is authorized to take all actions and execute all documents necessary or appropriate to effectuate the assumption and assignment of the Designated Assigned Contracts to PTC consistent with this Order, the PTC Sale Order, and the Purchase Agreement.

4. The terms and conditions of this Order shall be immediately effective and enforceable upon its entry and not subject to any stay.

5. This Court shall retain jurisdiction and power over any and all matters arising from or related to this Order.

Dated: October 2nd, 2026
Wilmington, Delaware

CRAIG T. GOLDBLATT
UNITED STATES BANKRUPTCY JUDGE

Exhibit 1

Designated Assigned Contracts

Contract Counterparty	Contract Description	Cure Amount[1]
Medpace Australia Pty. Ltd.	Local Sponsor Agreement dated January 11, 2021	$0.00
Medpace Germany GmbH	Assignment	$0.00
Medpace, Inc.	Termination dated May 2, 2024	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated February 22, 2017	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated June 13, 2019	$0.00
Medpace, Inc.	Clinical Study Agreement dated September 15, 2021	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated January 7, 2010	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated March 17, 2021	$0.00
Medpace, Inc.	Letter of Authorization dated October 19, 2021	$0.00
Medpace, Inc.	Letter of Intent dated June 26, 2017	$0.00
Medpace Research, Inc.	Letter of Intent dated November 27, 2018	$0.00
Medpace Research, Inc.	Amendment #1 to Letter of Intent dated February 1, 2019	$0.00
Medpace Research, Inc.	Termination dated April 5, 2022	$0.00
Medpace UK Ltd.	Non-Interventional Study Agreement	$0.00
Q-Square Business Intelligence, Inc.	Master Services Agreement dated April 27, 2020	$0.00
Q-Square Business Intelligence, Inc.	Termination dated April 17, 2024	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #1 dated April 27, 2020	$0.00

[1] The Cure Amounts set forth herein do not reflect postpetition payments that have been made by the Debtor. Postpetition amounts arising under the Designated Assigned Contracts will be paid in the ordinary course and not in connection with payments made to satisfy the Cure Amounts.

Contract Counterparty	Contract Description	Cure Amount[1]
Q-Square Business Intelligence, Inc.	Statement of Work #2 dated November 5, 2020	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #9 dated January 25, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #4 dated November 15, 2021	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work 003SD101 dated February 28, 2023	$0.00
Q-Square Business Intelligence, Inc.	Amendment #1 to MSA dated November 6, 2020	$0.00
Q-Square Business Intelligence, Inc.	Amendment #1 to MSA dated December 22, 2021	$0.00
Q-Square Business Intelligence, Inc.	Change Order #1 to Statement of Work #6 dated December 9, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #10 dated April 22, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work for ST-920 BLA dated February 7, 2025	$0.00
Bioclinica, Inc.	Confidential Disclosure Agreement dated October 5, 2017	$0.00
Bioclinica, Inc.	Non-Disclosure Agreement dated February 17, 2016	$0.00
Bioclinica, Inc.	Confidential Disclosure Agreement dated March 29, 2021	$0.00
Helmut Schweiger, Clinical Research and Project Management (CRP)	Master Services Agreement, dated May 13, 2026	$7,717.50
PCI Pharma Services	Global Clinical Services Quality (Technical) Agreement dated November 4, 2021	$0.00